Big events for 2021 include the FDA’s decision on aducanumab and pivotal readouts in diabetes and autoimmunity, while investor enthusiasm will be closely monitored.
Sellside firefighting has saved the day for IGM, but Ash hears of some pretty potent anti-CD20 competition for the company.
December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.
The start of a pivotal trial of Glaxosmithkline’s RSV vaccine adds another late-stage project to the pipeline for this underserved disease category.
Pivotal data at the upcoming Ash conference make Novartis’s asciminib one of the highlights for oncology watchers.
Failure of BTK inhibition puts the pressure on Lilly, Regeneron and Astrazeneca to deliver with antibodies to treat severe Covid-19.
Despite the phase II failure, Chemocentryx is pushing on in hidradenitis suppurativa.